EMJ | Elevating the quality of healthcare globally
In this episode, Jonathan Sackier sits down with Tom Bradshaw to explore the rapidly evolving landscape of digital health. They discuss Bradshaw’s expertise in the clinical application of AI and digital technologies, his work with the NHS and private sector firms, and more.
CC B Ó-NC . Licence É Copyright 22 EMJ É August 22 É Neurology 51 Meeting Summary Nipocalimab, a high-affinity, fully human, aglycosylated, effectorless ...
CC Y-NC 4. Licence É Copyright 224 EM É October 224 É Oncology 25 stressed. However, work is still needed to identify which patients with dMMR EC might not benefit ...
Abbreviations Figure 3: ESR1-mutation prevalence rate by treatment line in tissue and liquid biopsy.17 Percentages have been rounded to the nearest whole number.
30 EM Ø September 2024 Ø Copyright 2024 EM Ø CC BY-NC 4.0 Licence Clinical Practice Insights for Hyperpigmentation Treatment Interview Summary Hyperpigmentation ...
30 Reproductive Health August 202 Copyright 202 EM CC Ó-NC .0 Licence Endometriosis, Endometrial Disorders, and Infertility: From Bench to Bedside SERUM PROGESTERONE ...
May 2, 2024 · Abbreviations: AML: acute myeloid leukemia; CCUS: clonal cytopenia of undetermined significance; del: deletion; EB: excess blasts; FISH: fluorescence in situ ...
Why EGFR Exon 21 L858R Mutations Should Be Treated Differently
BACKGROUND. EGFR gene mutations have been reported in 15–60% of non-small cell lung cancers (NSCLCs) with an important difference in prevalence between Eastern and Western populations. 1,2 The most common EGFR-activating mutations in NSCLC include in-frame deletions in exon 19 and a substitution in exon 21 (L858R) which account for 47% and 41%, respectively, of observed EGFR mutations in ...
Oct 4, 2024 · 2 Factor XI/XIa Inhibitors: What We Now Know Interview Interview Summary The emerging class of agents targeting factor XI/XIa offers the paradigm-
An Update on Medication-Related Osteonecrosis of the Jaw in …
May 31, 2023 · Key Points. 1. Patients with osteoporosis should be recognised as being at considerably reduced risk of medication-related osteonecrosis of the jaw (MRONJ) relative to oncology patients, and risk stratified accordingly to avoid unnecessary delays to treatment.